ASCO 2026 Updates in Metastatic Breast Cancer

In this podcast episode, Hope S. Rugo, MD, FASCO, and Nerea Lopetegui-Lia, MD, discuss practice-informing data presented at ASCO 2026 for patients with metastatic breast cancer, including:

Findings from SERENA-6 on ctDNA-guided treatment switching for emergent ESR1 mutations before radiographic progression, including updated PFS2 and downstream treatment outcomesEmerging precision strategies in HR-positive/HER2-negative advanced breast cancer from ELEVATE and PIKALO-1, including elacestrant plus capivasertib and mutant-selective PI3Kα inhibition with tersolisibFirst-line TROP2-directed ADC data from ASCENT-04, ASCENT-03, and TROPION-Breast02, with discussion of PFS2, subsequent therapy, immunotherapy eligibility, and treatment sequencing

Presenters: 
Hope S. Rugo, MD, FASCO  
Director, Women’s Cancer Program 
Division Chief, Breast Medical Oncology 
Professor, Department of Medical Oncology & Therapeutics Research 
City of Hope Comprehensive Cancer Center 
Professor Emeritus and Emeritus Winterhof Family Distinguished Professor of Breast Oncology 
University of California, San Francisco 
San Francisco, California 

Nerea Lopetegui-Lia, MD 
Assistant Professor 
Division of Medical Oncology, Breast Section 
Department of Internal Medicine 
The Ohio State University 
Columbus, Ohio 

Get access to all of our new podcasts by subscribing to the Decera Clinical Education [Oncology] Podcast on Apple Podcasts, YouTube Music, or Spotify.

Link to full program:
https://bit.ly/4x4u5AT

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.